The optimized cell manufacturing protocol described here may also be used to expand other virus or cancer antigen-specific CD4 T cells to accelerate clinical application of this promising therapeutic strategy that combines CD4 T cell enrichment with a potent lentivirus vector to create a unique immunotherapy for HIV disease. The gene discussed is CD4; the disease is cancer.